Front. Immunol. Frontiers in Immunology Front. Immunol. 1664-3224 Frontiers Media S.A. 10.3389/fimmu.2025.1571978 Immunology Correction Corrigendum: Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study Wiendl Heinz 1 * † Barkhof Frederik 2 3 Montalban Xavier 4 Achiron Anat 5 6 Derfuss Tobias 7 Chan Andrew 8 Hodgkinson Suzanne 9 Prat Alexandre 10 Leocani Letizia 11 12 13 Schmierer Klaus 14 15 Sellebjerg Finn 16 17 Vermersch Patrick 18 Jin Hulin 19 Chudecka Anita 20 Kloetgen Andreas 19 Lin Dongdong 21 Gardner Lidia 22 De Stefano Nicola 23 1 Department of Neurology, Institute of Translational Neurology, University of Münster, Münster, Germany 2 Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands 3 Queen Square Institute of Neurology and Centre for Medical Image Computing, University College London, London, United Kingdom 4 Department of Neurology-Neuroimmunology, Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitario Vall d’Hebron, Barcelona, Spain 5 Multiple Sclerosis Center, Sheba Academic Medical Center, Ramat Gan, Israel 6 Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel 7 Department of Neurology, University Hospital Basel, Basel, Switzerland 8 Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland 9 Ingham Institute for Applied Medical Research, University of New South Wales Medicine and Liverpool Hospital, Sydney, NSW, Australia 10 Department of Neurosciences, Université de Montréal, Montréal, QC, Canada 11 Department of Neurology, University Vita-Salute San Raffaele, Milan, Italy 12 Experimental Neurophysiology Unit, Scientific Institute IRCCS San Raffaele, Milan, Italy 13 Department of Neurorehabilitation Science, Casa di Cura Igea, Milan, Italy 14 The Blizard Institute, Centre for Neuroscience, Surgery and Trauma, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom 15 Clinical Board Medicine (Neuroscience), The Royal London Hospital, Barts Health NHS, Trust, London, United Kingdom 16 Danish MS Center, Department of Neurology, Copenhagen University Hospital - Rigshospitalet, Glostrup, Denmark 17 Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark 18 Univ. Lille, Inserm U1172 LilNCog, CHU Lille, FHU Precise, Lille, France 19 Clinical Measurement Sciences, Merck Healthcare KGaA, Darmstadt, Germany 20 Clinical Research Services, Cytel Inc., Geneva, Switzerland 21 Clinical Measurement Sciences, EMD Serono Research & Development Institute, Inc., an affiliate of Merck KGaA, Billerica, MA, United States 22 Neurology & Immunology Medical Unit, EMD Serono Research & Development Institute, Inc., an affiliate of Merck KGaA, Billerica, MA, United States 23 Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy

Edited and Reviewed by: Klaus Berek, Innsbruck Medical University, Austria

*Correspondence: Heinz Wiendl, heinz.wiendl@uniklinik-freiburg.de

†Present address: Heinz Wiendl, Department of Neurology and Neurophysiology, Freiburg University, Freiburg, Germany

 05 03 2025 2025 16 1571978 06 02 2025 24 02 2025 Copyright © 2025 Wiendl, Barkhof, Montalban, Achiron, Derfuss, Chan, Hodgkinson, Prat, Leocani, Schmierer, Sellebjerg, Vermersch, Jin, Chudecka, Kloetgen, Lin, Gardner and De Stefano 2025 Wiendl, Barkhof, Montalban, Achiron, Derfuss, Chan, Hodgkinson, Prat, Leocani, Schmierer, Sellebjerg, Vermersch, Jin, Chudecka, Kloetgen, Lin, Gardner and De Stefano

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A Corrigendum on Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study By Wiendl H, Barkhof F, Montalban X, Achiron A, Derfuss T, Chan A, Hodgkinson S, Prat A, Leocani L, Schmierer K, Sellebjerg F, Vermersch P, Jin H, Chudecka A, Kloetgen A, Lin D, Gardner L and De Stefano N (2025) Front. Immunol. 16:1512189. doi: 10.3389/fimmu.2025.1512189 multiple sclerosis cladribine tablets biomarkers transcriptomics immunophenotyping immune reconstitution therapy section-in-acceptance Multiple Sclerosis and Neuroimmunology

In the published article, there was an error in Figure 5 as published. In the figure, the legend for the blue and red dots incorrectly read as “|FC| <1.2 & FDR>0.05”. The legend for blue should read “|FC| <1.2 & FDR<0.05” and for red should read “|FC| >1.2 & FDR<0.05”. The corrected Figure 5 and its caption “Gene expression of CD3+ and CD19+ cells at M12, M15 and M24 compared to BL. BL, baseline; FC, fold change; FDR, false discovery rate; M, month.” appear below.

Gene expression of CD3+ and CD19+ cells at M12, M15 and M24 compared to BL. BL, baseline; FC, fold change; FDR, false discovery rate; M, month.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.